Articles related to Kenta Biotech

Partnering spotlight: Kenta Biotech anticipates the final phase IIA results of its fully human antibody by mid-2009

March 6, 2009 - Conference: - Company: - Tags:

A rare find among partnering candidates at BIO-Europe Spring® is Kenta Biotech offering late stage development opportunity for a family of four complementary antibodies targeting the most difficult to treat hospital infections, a market yet untouched by antibody therapies. The lead product is in Phase IIA for treatment of nosocomial pneumonia. The deal includes a Read more »

Newsletter

Subscribe to partneringNEWS
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.

Sign up today to the free newsletter and never miss any new content.